Method for determining the age of red blood cells

Glycated Hb was measured in reticulocytes (RNA-positive cells) and was correlated to a decrease in RNA fluorescence intensity in a Log-linear […]

Use of vdac and lamp1 as markers for detecting pocked red blood cells

Counting vacuole-containing RBC (pocked-RBC) is a robust marker of defective spleen function but requires the expertise of fewer and fewer specialized […]

Method for determining the relative age of red blood cells

Glycated Hb was measured and compared between five healthy donors (AA), seven non-diabetic and non-transfused homozygous SCD patients (SS) and five […]

Methods and kits for identifying and quantifying storage-induced

Refrigerated storage of red cell concentrates (RCC) for transfusion is associated with the accumulation of various alterations to the red blood cells […]

Methods for increasing fetal hemoglobin content in eukaryotic cells

The clinical severity of ?-hemoglobinopathies is alleviated by the co-inheritance of genetic mutations causing a sustained fetal ?-globin chain […]

Use of il-6 inhibitors for the treatment of acute chest syndrome in

Acute chest syndrome (ACS) is a common and potentially lethal form of acute lung injury in sickle cell disease (SCD). Because pathophysiology remains […]

Anti- protease nexin-1 conformational single domain antibodies and

The present invention relates to anti-protease nexin-1 (PN-1) conformational single domain antibodies and uses thereof in particular in the […]

Correction of beta-thalassemia phenotype by genetically engineered

The present invention relates to a genetically modified hematopoietic stem cell(HSC) comprising, in at least one ?-globin gene comprised in the genome […]

Combination of arsenic and interferon alpha for the treatment of

The present invention relates to methods and pharmaceutical compositions for the treatment of myeloproliferative disorders in patients presenting a […]

Protease nexin-1 inhibitor for the treatment of haemorrhagic disease

The thrombogram of FVIII-KO mice displays a prolonged time to peak and a reduced peak thrombin. The addition of the neutralizing anti-protease nexin-1 […]